We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Therapeutic Approach Floods Prostate Cancer Cells with Copper

By LabMedica International staff writers
Posted on 26 Oct 2014
Print article
A novel approach for treating prostate cancer is based on the co-administration of the drug disulfiram and copper, an element that the growing cancer cells require.

Serum copper levels have been found to be elevated in patients with prostate cancer, and increased copper uptake can be used as a means to image prostate tumors. It is unclear, however, to what extent copper is required for prostate cancer cell function as previous chelation strategies to treat the disease produced only modest effects on the growth of these cells in vitro.

In a paper published in the October 15, 2014, issue of the journal Cancer Research, investigators at Duke University (Durham, NC, USA) described screening libraries of thousands of approved drugs to identify those that rely on copper to achieve their results. Among the candidate compounds was disulfiram, a drug approved by the [US] Food and Drugs Administration to treat alcoholism. Disulfiram acts by inhibiting the enzyme acetaldehyde dehydrogenase, which slows the removal of acetaldehyde. Build-up of acetaldehyde causes vasomotor disturbances, nausea, vomiting, and even unconsciousness and death.

The investigators found that disulfiram alone had only a minimal effect on the growth of prostate cancer tumors propagated as xenografts in mice. However, when the drug was co-administered with copper, a very dramatic inhibition of tumor growth in models of hormone-sensitive and of castrate-resistant disease was observed. In addition, they determined that prostate cancer cells expressed high levels of CTR1, the primary copper transporter, and additional chaperones that were required to maintain intracellular copper homeostasis. The expression levels of most of these proteins were increased further upon treatment of androgen receptor (AR)–positive prostate cancer cell lines with androgens. Robust CTR1-dependent uptake of copper into prostate cancer cells was observed, an activity that was accentuated by activation of the androgen receptor.

"Our first efforts were to starve the tumors of copper, but that was unsuccessful. We could not deplete copper enough to be effective," said senior author Dr. Donald McDonnell, professor of pharmacology and cancer biology at Duke University. "So we thought if we cannot get the level low enough in cancer cells to kill them, how about we boost the copper and then use a drug that requires copper to be effective to attack the tumors. It is the old if-you-cannot-beat-them-join-them approach."

"Unfortunately, hormone therapies do not cure prostate cancer, and most patients experience relapse of their disease to a hormone-refractory or castration-resistant state," said Dr. McDonnell. "Although tremendous progress has been made in treating prostate cancer, there is clearly a need for different approaches, and our findings provide an exciting new avenue to explore. This proclivity for copper uptake is something we have known could be an Achilles' heel in prostate cancer tumors as well as other cancers."

Related Links:

Duke University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.